Abstract:Westernization of dietary habits increases lipid intake and is responsible for increased numbers of patients with atherosclerotic diseases. Niemann-Pick C1-Like 1 (NPC1L1)-a cholesterol importer-plays a crucial role in dietary cholesterol absorption in the intestine and is closely associated with several lipid-related diseases, including atherosclerosis. NPC1L1 is highly expressed in the liver and intestine in humans, whereas NPC1L1 expression is low in the rodent liver. Due to species differences in the tissue distribution of NPC1L1, there are limited studies on the pathophysiological role of hepatic NPC1L1, a cholesterol reabsorber from bile. In the present study, to explore whether hepatic NPC1L1 is involved in the development/progression of atherosclerosis, we compared four kinds of atherosclerosis mouse models with different expression levels of NPC1L1 in the intestinal and liver tissues in a genetic background of dysfunctional low-density lipoprotein receptor mutation. Western diet (WD)-induced hyperlipidemia and atherosclerotic plaque formation were more severe in mice expressing NPC1L1 in both the liver and intestine (plasma cholesterol, 839.5 mg/dl; plaque area, 29.5% of total aorta), compared with mice expressing NPC1L1 only in the intestine (plasma cholesterol, 573.1 mg/dl; plaque area, 13.3% of total aorta). Such hepatic NPC1L1-mediated promotion of hyperlipidemia and atherosclerosis was not observed in mice not expressing intestinal NPC1L1 and mice treated with ezetimibe, an NPC1L1 inhibitor used clinically for dyslipidemia. These results suggested that hepatic NPC1L1 promotes WD-induced dyslipidemia and atherosclerosis in concert with intestinal NPC1L1. Our findings provide novel insights into the pathophysiological importance of hepatic NPC1L1 in development/progression of atherosclerosis. SIGNIFICANCE STATEMENT: Niemann-Pick C1-Like 1 (NPC1L1) protein, a cholesterol importer and a molecular target of ezetimibe clinically used for dyslipidemia, is highly expressed not only in the intestine, but also in the liver in humans, although the pathophysiological importance of hepatic NPC1L1 in atherosclerotic diseases remained unclear. By using novel mouse models to separately analyze the effects of hepatic and intestinal NPC1L1 on the development/progression of atherosclerosis, we first demonstrated that hepatic NPC1L1 accelerates Western diet-induced atherosclerotic plaque formation in an intestinal NPC1L1-dependent and an ezetimibe-sensitive manner.

NPC1L1 Deficiency Suppresses Ileal Fibroblast Growth Factor 15 Expression and Increases Bile Acid Pool Size in High-Fat-Diet-Fed Mice

Niemann-Pick C1-Like 1 Deletion in Mice Prevents High-Fat Diet-Induced Fatty Liver by Reducing Lipogenesis

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Hepatic NPC1L1 Promotes Hyperlipidemia in LDL Receptor Deficient Mice

Small Heterodimer Partner and Fibroblast Growth Factor 19 Inhibit Expression of NPC1L1 in Mouse Intestine and Cholesterol Absorption

Ezetimibe Restores Biliary Cholesterol Excretion in Mice Expressing Niemann-Pick C1-Like 1 Only in Liver.

Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice

FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice

NPC1L1 Plays a Novel Role in Nonalcoholic Fatty Liver Disease

Insulin-like Growth Factor Binding Protein 1 Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease

Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice

Overexpression of Npc1l1 in the Livers of Transgenic Bama Miniature Pigs Accelerates Lipid Peroxidation

Ezetimibe Inhibits Hepatic Niemann-Pick C1-Like 1 to Facilitate Macrophage Reverse Cholesterol Transport in Mice

NPC1L1 Facilitates Sphingomyelin Absorption and Regulates Diet-Induced Production of VLDL/LDL-associated S1P

Hepatocyte CD36 protects mice from NASH diet-induced liver injury and fibrosis via blocking N1ICD production

Bile Acids-Mediated Intracellular Cholesterol Transport Promotes Intestinal Cholesterol Absorption and NPC1L1 Recycling

Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A

Fat-1 Mice Prevent High-Fat Plus High-Sugar Diet-Induced Non-Alcoholic Fatty Liver Disease

Regulation of Bile Acid Biosynthesis by Hepatocyte Nuclear Factor 4Α

The Development of the Key PNPC1L1 in Cholesterol Transport

Cyp1b1 Deficiency Ameliorates Obesity and Glucose Intolerance Induced by High Fat Diet in Adult C57bl/6j Mice